NCI’s IMAT Program seeks R33 projects to advance and rigorously validate tools, devices, assays, and methods that improve the collection, handling, preservation, storage, and quality assessment of cancer-relevant biospecimens. Technologies must show prior feasibility, deliver transformative, quantifiable performance improvements, and accelerate cancer research or care—including in low-resource and disparity-impacted settings. Clinical trials are not allowed.
Eligibility Criteria:
-
Eligible applicants include higher-education institutions, nonprofits, for-profits (including small businesses), government entities, tribal organizations, school districts, housing authorities, faith/community organizations, regional organizations, and foreign organizations.
-
Foreign organizations and foreign components of U.S. organizations are eligible.
-
PD/PI must have an eRA Commons ID; organizational registrations required (SAM with UEI, Grants.gov, eRA Commons).
-
Multiple scientifically distinct applications per organization are allowed.
Funding Details:
-
Mechanism: R33 (Exploratory/Developmental Phase II).
-
Clinical trial: not allowed.
-
Budget: up to 300,000 USD in direct costs per year.
-
Project period: up to 3 years.
Deadline:
-
Due date: October 3, 2025, by 5:00 PM local time of applicant organization.
Where to go for further information:
-
Scientific contact: Kelly Crotty, Ph.D. — [email protected].
-
Peer review contact: Referral Officer — [email protected].
-
Grants management: Sean Hine — [email protected].
-
General help: eRA Service Desk; [email protected].